Medipharm Worldwide Group SRL
Medipharm Worldwide Group reported total assets of 331,081 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Aug 2026).
The score of Medipharm Worldwide Group shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Medipharm Worldwide Group's annual accounts
| 2025 | |
|---|---|
| Net result | 167,904 € |
| Equity | 217,904 € |
| Cash | 113,421 € |
| Total assets | 331,081 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Aug 2026
Medipharm Worldwide Group's financial analysis
- Solvency65.8%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Medipharm Worldwide Group
Medipharm Worldwide Group's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1017.902.558
- VAT number
- BE1017902558
- Peppol
- Registered · 0208:1017902558 · as of 12 Nov 2026
- Legal form
- SRL
- Incorporated
- 24 Dec 2024
- Registered office
- 3300 Tienen
- Latest accounts
- 2025 · filed on 29 Aug 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Medipharm Worldwide Group (SRL) has been based in Tienen since 2024, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of 167,904 € and equity of 217,904 €; its revenue is not published. Its solvency stands at 65.8%, above the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Medipharm Worldwide Group
Companies in the same business, of comparable size and area, outside its group.
- QP Pro Services Manufacture of basic pharmaceutical products Gembloux · balance sheet 304,804 €
- huMAN Manufacture of basic pharmaceutical products Gerpinnes · balance sheet 186,227 €
- Yaro Preclinical Consulting Manufacture of basic pharmaceutical products Turnhout · balance sheet 158,481 €
- Care4Excellence Manufacture of pharmaceutical preparations Overijse · balance sheet 307,250 €
- MDT Services & Technologies Manufacture of basic pharmaceutical products Lontzen · balance sheet 102,386 €
- Pharma MAR Manufacture of basic pharmaceutical products Brussels · balance sheet 492,662 €
- Clinical Research Vanackere Manufacture of basic pharmaceutical products Tielt-Winge · balance sheet 263,927 €
- Joos Clinical Projects Manufacture of basic pharmaceutical products Destelbergen · balance sheet 549,074 €
Frequently asked questions about Medipharm Worldwide Group
What is the revenue of Medipharm Worldwide Group?
Medipharm Worldwide Group files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Medipharm Worldwide Group?
In Belgium, the VAT number is the company number prefixed with BE: BE1017902558 for Medipharm Worldwide Group, if the company is VAT-registered. Its company number (CBE) is 1017.902.558.
Where is the registered office of Medipharm Worldwide Group?
According to the CBE register, the registered office of Medipharm Worldwide Group is in 3300 Tienen.
What is the equity of Medipharm Worldwide Group?
At the close of the 2025 financial year, the equity of Medipharm Worldwide Group amounts to 217,904 €, a solvency of 65.8% of total assets.
Who manages Medipharm Worldwide Group?
The register lists 1 active mandates at Medipharm Worldwide Group. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Medipharm Worldwide Group
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →